The predictive value of tumor mutation burden for immune checkpoint inhibitors therapy in non-small cell lung cancer is affected by patients’ age

Abstract High tumor mutation burden (TMB), which is associated with increased tumor immunogenicity, has been identified to predict improved response to immune checkpoint inhibitors (ICIs) therapy in non-small cell lung cancer (NSCLC). As host immunity is also significant to eliminate cancer cells, h...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Yongfeng Wu, Jinming Xu, Jiawei Xu, Yiqing Wang, Luming Wang, Wang Lv, Jian Hu
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2020-04-01
coleção:	Biomarker Research
Assuntos:	Tumor mutation burden TMB Age Immune checkpoint inhibitor ICI NSCLC
Acesso em linha:	http://link.springer.com/article/10.1186/s40364-020-00188-2
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!